Summary:
Randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and pharmacokinetics of different dosing regimens of Favipiravir in healthy adults and adults with uncomplicated Influenza.
Qualified Participants Must:
• Be between 18 and 80 years of age
•
Have been diagnosed with the Flu in the last 48 hours, or had 2 or more of these symptoms: cough, sore throat, headache, nasal congestion, body aches and pains, fatigue fever 100.4 or higher
•
Or having symptoms and exposed to someone diagnosed with the flu
Qualified Participants May Receive:
Study flu medication that may help manage flu symptoms, study related medical care and compensation for time and travel.